David Melnick has joined Spero Therapeutics (NASDAQ: [[ticker:SPRO]]) to become the Cambridge, MA, company’s chief medical officer. Melnick served as vice president of clinical development for anti-infectives at Allergan (NYSE: [[ticker:AGN]]) since 2015. Spero has two clinical-stage antibiotics that the company hopes can help address the growing problem of drug-resistant bacteria.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
